Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC publishes new report on treatments for chronic myeloid leukaemia (CML)

Published: 31 July 2012
Report on treatments for CML

A systematic review and economic evaluation on treatments for chronic myeloid leukaemia is now available.

The report ‘Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation' is freely available from the NIHR HTA Programme website. The report identifies limited new information on the clinical effectiveness of these treatments in those with CML which is resistant to standard-dose imatinib, but suggests that the interventions can lead to improvements in haematological and cytogenetic responses. The SHTAC report is a supplement to Thompson-Coon et al. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid Leukaemia: A systematic review and economic evaluation. Health Technology Assessment 2012;16(22).  For more on SHTAC's research on  cancer visit our Research page.


Privacy Settings